Sign in to view content

Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials

Dilsher S. Dhoot, MD

Video
Published 2021

Related

What Is the Clinical Significance of Improving Diabetic Retinopathy for Vision Outcomes? A Meta-Analysis of 5 Ranibizumab Trials
Sophie Jane Bakri, MD
Annual Meeting Talks
2021
Tarcocimab Tedromer (KSI-301) Anti-VEGF Antibody Biopolymer Conjugate for DME: First-Time Efficacy, Durability and Safety Results of the GLEAM and GLIMMER Phase 3 studies
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2023
Assessment of Central Subfield Thickness Fluctuations and Impact on Vision in Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS)
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more